Geron | GERN - Current Liabilities


Geron reported $73.57M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Amgen USD 24.96B 534M Mar/2026
Bio Techne USD 153.28M 12.85M Mar/2026
Cassava Sciences USD 40.11M 3.72M Mar/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
Esperion Therapeutics USD 300.36M 451K Mar/2026
Exelixis USD 370.98M 34.67M Mar/2026
Genmab DKK 1.43B 686M Dec/2025
Geron USD 73.57M 40.25M Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
MacroGenics USD 95.94M 52.82M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Novavax USD 342.46M 117.49M Mar/2026